Costs of Respiratory Syncytial Virus Hospitalizations in Colombia
PharmacoEconomics - Open - 2020
Tóm tắt
Several clinical practice guidelines exist for the management of respiratory syncytial virus (RSV) infection, but the use and overuse of medications and medical tests with insufficient evidence of effectiveness remains substantial. This study aimed to evaluate the medical costs associated with bronchiolitis hospitalizations caused by RSV infection among infants aged < 2 years in Colombia. This was a prevalence-based cost-of-illness multicentric study performed from the societal perspective during 2016–2017. A case was defined as a laboratory-confirmed RSV infection with hospitalization. All costs and use of resources were collected directly from medical invoices and health records. This study included 193 patients with a diagnosis of RSV. The average hospital stay duration was 5.55 days. The major contributors to hospitalization costs were room costs (31.5%), drugs (21.8%), and indirect costs (14.9%). Medications with the highest costs were nebulization with a hypertonic solution and systemic antibiotics. In total, 96% of β-lactam antibiotics, 90% of bronchodilators, and 86% of corticosteroids and epinephrine were classified as inappropriate. RSV infection in Colombia places a high economic burden on the health system. Generating comprehensive data on healthcare resource use and costs associated with RSV will help to provide valuable information for the development of cost-effectiveness models and to guide RSV-prevention strategies.
Từ khóa
Tài liệu tham khảo
Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58.
Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545–55.
Drysdale SB, Sande CJ, Green CA, Pollard AJ. RSV vaccine use–the missing data. Expert Rev Vaccines. 2016;15(2):149–52.
Colombia., Ministerio de Salud y Protección Social, Antioquia. Ud. Guía de padres y cuidadores para la evaluación del riesgo y manejo inicial de la neumonía en niños y niñas menores de 5 años y bronquiolitis en niños y niñas menores de 2 años. 2014. https://gpc.minsalud.gov.co/gpc_sites/Repositorio/Otros_conv/GPC_neumonia/GPC_neumonia_completa.aspx.
Kou M, Hwang V, Ramkellawan N. Bronchiolitis: from practice guideline to clinical practice. Emerg Med Clin North Am. 2018;36(2):275–86.
Ochoa Sangrador C, Gonzalez de Dios J, Research Group of the A BP. Overuse of bronchodilators and steroids in bronchiolitis of different severity: bronchiolitis-study of variability, appropriateness, and adequacy. Allergol Immunopathol (Madr). 2014;42(4):307–15.
Florin TA, Byczkowski T, Ruddy RM, Zorc JJ, Test M, Shah SS. Variation in the management of infants hospitalized for bronchiolitis persists after the 2006 American Academy of Pediatrics bronchiolitis guidelines. J Pediatr. 2014;165(4):786–92 e1.
Sarmiento L, Rojas-Soto GE, Rodriguez-Martinez CE. Predictors of inappropriate use of diagnostic tests and management of bronchiolitis. Biomed Res Int. 2017;2017:9730696.
Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PA, Hagan J, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child. 2004;89(7):673–8.
Rodriguez Martinez CE, Sossa Briceno MP. Cost-effectiveness of chest x-rays in infants with clinically suspected viral bronchiolitis in Colombia. Rev Panam Salud Publica. 2011;29(3):153–61.
Diez-Domingo J, Perez-Yarza EG, Melero JA, Sanchez-Luna M, Aguilar MD, Blasco AJ, et al. Social, economic, and health impact of the respiratory syncytial virus: a systematic search. BMC Infect Dis. 2014;14:544.
Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics. 2004;22(5):275–84.
Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA. Direct medical costs of RSV-related bronchiolitis hospitalizations in a middle-income tropical country. Allergol Immunopathol (Madr). 2019.
Departamento, Administrativo Nacional Estadisticas. Índice de Precios al Consumidor – IPC. 2020. https://www.dane.gov.co/index.php/estadisticas-por-tema/precios-y-costos/indice-de-precios-al-consumidor-ipc.
Sinisterra D, Buendía J. Cost illness of Rsv infection in Colombia. Value Health. 2017;20(9):A923–A4.
Departamento, Administrativo, Nacional, Estadisticas. Proyecciones de poblacion. 2018. https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/proyecciones-de-poblacion. Accessed from 03 Jul 2019.
la Bd, Republica. Tasa Representativa del Mercado (TRM - Peso por dólar). 2019. https://www.banrep.gov.co/es/estadisticas/trm(cited 2020)
Departamento, Nacional, (DANE) DE. Archivo Nacional de Datos. 2019. https://sitios.dane.gov.co/anda-index/.
Bhuiyan MU, Luby SP, Alamgir NI, Homaira N, Sturm-Ramirez K, Gurley ES, et al. Costs of hospitalization with respiratory syncytial virus illness among children aged %3c5 years and the financial impact on households in Bangladesh, 2010. J Glob Health. 2017;7(1):010412.
Zhang T, Zhu Q, Zhang X, Ding Y, Steinhoff M, Black S, et al. Clinical characteristics and direct medical cost of respiratory syncytial virus infection in children hospitalized in Suzhou. China Pediatr Infect Dis J. 2014;33(4):337–41.
Zepeda TJ, Vasquez ZJ, Delpiano ML. Direct costs of low respiratory infection due to RSV in children under one year. Rev Chil Pediatr. 2018;89(4):462–70.
Antonio Buendia J, Colantonio L. Costo-Efectividad de la Proteina C Reactiva, Procalcitonina y Escala de Rochester: Tres Estrategias Diagnosticas para la Identificacion de Infeccion Bacteriana Severa en Lactantes Febriles sin Foco. Value Health Reg Issues. 2013;2(3):375–80.
Buendia JA, Sanchez-Villamil JP, Urman G. Cost-effectiveness of diagnostic strategies of severe bacterial infection in infants with fever without a source. Biomedica. 2016;36(3):406–14.
Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–e15021502.
Buendia JA, Zuluaga AF. Physicians insight about adverse drug reaction to frequently used medication groups in Bogota (Colombia). Biomedica. 2014;34(3):403–8.
Samson L, Cooke C, Macdonald N. Analysis of antibiotic use and misuse in children hospitalized with RSV infection. Paediatr Child Health. 1999;4(3):195–9.
Patra S, Singh V, Pemde HK, Chandra J. Antibiotic prescribing pattern in paediatric in patients with first time wheezing. Ital J Pediatr. 2011;37:40.
Amand C, Tong S, Kieffer A, Kyaw MH. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis. BMC Health Serv Res. 2018;18(1):294.
Chen IL, Huang HC, Chang YH, Huang HY, Yeh WJ, Wu TY, et al. Effect of antibiotic use for acute bronchiolitis on new-onset asthma in children. Sci Rep. 2018;8(1):6090.
Jacobs P, Fassbender K. The measurement of indirect costs in the health economics evaluation literature. A review. Int J Technol Assess Health Care. 1998;14(4):799–808.
Lensberg BR, Drummond MF, Danchenko N, Despiegel N, Francois C. Challenges in measuring and valuing productivity costs, and their relevance in mood disorders. Clinicoecon Outcomes Res. 2013;5:565–73.
42.691 DoN. Decreto 2443 de 1996. 1996. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/decreto-2423-de-1996.pdf. Accessed on 26 Jul 2019.